Dear Tigermed Family,
As we bid farewell to 2023 and welcome the New Year, in this moment of beauty and significance, we’d like to extend our warm New Year's greetings and heartfelt wishes to each of you and your families!
Working together we have made good progress toward our strategic goals despite significant challenges, and steadfastly pursued our three pillars: globalization, integration, and digitalization.
We are proud to see how quickly we adapted to each new challenge and how teams across countries and continents collaborated to make the most of every opportunity. Your resilience, expertise, dedication, and innovation have been instrumental in our achievements.
In 2023, our integrated R&D platforms took a real step forward, providing innovative solutions across the drug and medical device lifecycles. We also launched new capabilities in early-phase medical transformation and comprehensive enterprise services, reflecting our continuous progress in Tigermed's integrated services offerings.
We also took important steps on digital capabilities to significantly enhance efficiency. The rollout of digital systems and solutions has added new momentum to our capabilities. Our decentralized clinical trial solutions are now applied across diverse therapeutic areas, enabling remote follow-up, monitoring, eConsent and more. We've also published the "DCT Global Regulatory Manual", with key guidance for worldwide applications.
The establishment of our International Headquarters in Hong Kong marked another significant milestone in our global development and operations. Our capabilities in North America, Europe, Asia-Pacific, and others continue to expand, leading to the increasing recognition of our global services by customers.
Our environmental, social, and governance (ESG) initiatives have earned us an upgrade to AA status by MSCI, reaffirming our commitment to being a sustainable business and creating a positive impact in the industry.
Over the past year, you’ve all demonstrated over and over again our strengths as an organization and made clear that when it comes to Tigermed, the whole is greater than the sum of the parts.
The work we are doing is more relevant than ever today. The solutions we provide are an integral part of human health, and our customers rely on us to keep life science breakthroughs forward and save patients’ lives.
We want to thank you for your continued commitment and effort. Every one of us has an important role to play in the work ahead, and I’m confident that together we will achieve great things. Our commitment to innovation remains unwavering as we step into 2024.
We wish you and your families a very happy and successful 2024!
Sincerely,
Xiaoping Ye, PhD, Co-Founder and Chairman
Xiaochun Cao, PhD, Co-Founder and President
Hao Wu, Co-President
